瑞普生物(300119) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥836,737,374.53, representing a year-on-year increase of 1.44%[5] - Net profit attributable to shareholders for Q3 2025 was ¥105,784,584.02, up 23.02% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥81,536,762.58, reflecting a 7.64% increase year-on-year[5] - For the first nine months of 2025, the company achieved a total revenue of ¥2,544,325,031.33, a 13.50% increase from the previous year[9] - The net profit attributable to shareholders for the first nine months was ¥362,307,052.90, which is a 45.64% increase year-on-year[9] - Operating profit for the current period was ¥442,271,734.21, up 39.6% from ¥316,434,076.01 in the previous period[27] - Net profit attributable to shareholders of the parent company was ¥362,307,052.90, representing a 45.6% increase from ¥248,766,437.96 in the previous period[28] - Earnings per share (EPS) for the current period was ¥0.7972, up from ¥0.5401 in the previous period[28] Cash Flow and Assets - The company's cash flow from operating activities for the first nine months was ¥205,880,305.22, down 45.46% compared to the previous year[11] - The company's short-term borrowings decreased to 736.81 million yuan from 800.78 million yuan[25] - Accounts payable decreased to 320.68 million yuan from 362.87 million yuan[25] - The company reported a net cash flow from operating activities of ¥205,880,305.22, down 45.4% from ¥377,458,172.51 in the previous period[30] - The company generated cash inflows from investment activities totaling ¥2,254,967,689.98, a decrease from ¥2,604,449,087.07 in the previous period[30] - Cash and cash equivalents at the end of the period increased to $486.83 million, up from $350.51 million, representing a growth of approximately 39%[31] - The company’s cash flow from investment activities showed a net inflow of $60.29 million, a turnaround from a net outflow of -$269.18 million previously[31] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥7,690,888,248.95, a decrease of 3.45% from the end of the previous year[5] - Total liabilities decreased to ¥2,540,845,487.30 from ¥2,958,832,996.02, a reduction of 14.1%[26] - Total equity increased to ¥5,150,042,761.65 from ¥5,006,960,057.85, reflecting a growth of 2.8%[26] - Current assets totaled 3.61 billion yuan, a decrease from 3.65 billion yuan at the start of the period[24] - The company's non-current assets totaled 4.08 billion yuan, down from 4.32 billion yuan at the beginning of the period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,144[13] - The largest shareholder, Li Shoujun, holds 36.04% of shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[13] - The second-largest shareholder, Liang Wu, holds 5.04% of shares, totaling 23,405,578 shares, with 11,730,000 shares pledged[13] - The total number of restricted shares at the beginning of the period was 130,866,730, with 1,093,425 shares released and 19,380 shares added, resulting in 129,792,685 restricted shares at the end of the period[17] - The company has a high concentration of ownership, with the top five shareholders holding over 50% of the total shares[13] - The company has not reported any changes in the number of preferred shareholders or their holdings[15] Research and Development - Research and development expenses rose to ¥157,025,388.67, an increase of 16.2% compared to ¥135,162,744.28 in the previous period[27] - The company received clinical trial approval for the world's first mRNA vaccine for food animals, enhancing its product line and industry reputation[18] - In Q3, the company obtained approvals for 7 new veterinary products, including vaccines and antibiotics, to strengthen its product matrix in the pet and livestock medicine sectors[18] Investments and Projects - The company has changed part of its fundraising purpose to invest 296 million yuan in a microbial protein industrialization project, with a total investment of 679 million yuan[20] - A joint venture was established with Shengwei Biotechnology to develop vaccines for ruminants, with the company investing 27 million yuan for a 43.55% stake[22] Other Financial Information - The company completed the cancellation of 1,093,200 restricted stock units, reducing its registered capital from 465,847,906 yuan to 464,754,706 yuan[21] - The impact of exchange rate changes on cash and cash equivalents was a positive $196,030.85, down from $392,159.94, reflecting a decrease of approximately 50%[31] - The third quarter financial report was not audited, which may affect the reliability of the reported figures[32]